Can a Common Vitamin Fight the Most Aggressive Brain Cancer?

Researchers at the University of Calgary tested high-dose controlled-release niacin added to standard glioblastoma care in a Phase I/II trial.

Interim results from 24 patients showed 82% progression-free survival at six months, a 28% improvement over historical data.

Preclinical mouse studies showed niacin extended survival and reduced tumor growth.

Investigators caution that larger enrollment and safety monitoring are required before drawing conclusions.